ClinicalTrials.gg
Active, not recruitingNCT07441252Updated Sep 28, 2026

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

A Phase 2 interventional study of Maridebart cafraglutide and Placebo in Overweight or Obesity and Elevated Liver Fat, sponsored by Amgen. Active, not recruiting at 23 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Updated Sep 28, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Planned enrollment
18th of 28
180 · median 275
Started
2026
with 9 others
Phase 2
3 of 28
none open now
Primary completion
2027-08
later than 7 of 16 live
Registered
16th of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 18th largest by planned enrollment, is one of 10 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 7 of the 16 other live ones, and was the 16th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.

03

Conditions studied

  • Overweight or Obesity and Elevated Liver Fat

Browse trials for

Keywords

  • Obesity
  • Overweight
  • Elevated liver fat
  • AMG 133
  • Maridebart cafraglutide
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 180 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • (BMI) ≥ 27 kg/m\^2 to ≤ 40 kg/m\^2 at screening.
  • For participants with type 2 diabetes mellitus (T2DM) at screening:
  • ≤ 9.5% (80 mmol/mol) at screening.
  • Treated with diet and exercise alone and/or a stable treatment with metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, or combination.
  • Liver Controlled Attenuation Parameter (CAPTM) ≥ 300 dB/meter via FibroScan® assessment.
  • Liver fat content ≥ 10% by MRI as determined by the central imaging vendor at screening.
  • MRI assessment should only be performed after all other eligibility has been confirmed whenever possible.
  • History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.

Exclusion criteria

Exclusion Criteria:

  • Recent or planned surgical/device-based obesity treatment (\<1 year).
  • History of within the past 5 years (exceptions apply).
  • Type 1 diabetes or non-type 2 diabetes mellitus (T2DM); unstable/severe hypoglycemia.
  • Advanced diabetic retinopathy or macular edema.
  • History of pancreatitis (acute \<180 days or chronic).
  • History of medullary thyroid carcinoma (MTC) or MEN-2
  • Major cardiovascular event within 60 days (e.g., myocardial infarction [MI], stroke, coronary artery bypass graft [CABG]).
  • (NYHA) Class IV heart failure.
  • Unstable psychiatric disorders within 2 years.
  • Significant liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD) (e.g., hepatitis, cirrhosis, hepatic decompensation).
  • Estimated (eGFR) \< 30 mL/min/1.73 m\^2 or on dialysis.
  • Patient Health Questionnaire-9 (PHQ-9) ≥ 15, or suicidal ideation/behavior (Columbia-Suicide Severity Rating Scale [C-SSRS]).
  • Inability to undergo MRI scan (e.g., due to metal implant, claustrophobia, or body size limitations).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Maridebart Cafraglutide

    Participants will receive maridebart cafraglutide as a subcutaneous (SC) injection every 4 weeks (Q4W) for 52 weeks.

    Drug: Maridebart cafraglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo as a SC injection Q4W for 52 weeks.

    Drug: Placebo

Interventions

  • Maridebart cafraglutide will be administered as a SC injection.

    Also known as: AMG 133

  • DrugPlacebo

    Placebo will be administered as a SC injection.

07

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52

    Time frame: Baseline and Week 52

  2. Percent Change from Baseline in Body Weight at Week 52

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Number of Participants Achieving ≥ 30% Reduction from Baseline in Liver Fat Content (LFC) by MRI at Week 52

    Time frame: Baseline and Week 52

  2. Percent Change from Baseline in Visceral Adipose Tissue (VAT) Volume by MRI at Week 52

    Time frame: Baseline and Week 52

  3. Number of Participants Achieving < 5% LFC by MRI at Week 52

    Time frame: Week 52

  4. Change from Baseline in LFC by MRI at Week 52

    Time frame: Baseline and Week 52

  5. Percent Change from Baseline in LFC by MRI at Week 24

    Time frame: Baseline and Week 24

  6. Change from Baseline in LFC by MRI at Week 24

    Time frame: Baseline and Week 24

  7. Percent Change from Baseline in Thigh Muscle Volume by MRI at Week 24 and Week 52

    Time frame: Baseline, Week 24, and 52

  8. Percent Change from Baseline in Thigh Muscle Fat Fraction by MRI at Week 24 and Week 52

    Time frame: Baseline, Week 24, and 52

  9. Percent Change from Baseline in Thigh Intermuscular and Intramuscular Fat Volume by MRI at Week 24 and Week 52

    Time frame: Baseline, Week 24, and 52

  10. Percent Change from Baseline in Abdominal Subcutaneous Adipose Tissue (ASAT) Volume by MRI at Week 52

    Time frame: Baseline and Week 52

  11. Percent Change from Baseline in VAT Volume by MRI at Week 24

    Time frame: Baseline and Week 24

  12. Percent Change from Baseline in ASAT Volume by MRI at Week 24

    Time frame: Baseline and Week 24

  13. Change from Baseline in Waist Circumference at Week 52

    Time frame: Baseline and Week 52

  14. Change from Baseline in Waist-to-height Ratio at Week 52

    Time frame: Baseline and Week 52

  15. Change from Baseline in Aspartate Aminotransferase (AST) at Week 52

    Time frame: Baseline and Week 52

  16. Change from Baseline in Alanine Aminotransferase (ALT) at Week 52

    Time frame: Baseline and Week 52

  17. Change from Baseline in Gamma Glutamyl Transferase (GGT) at Week 52

    Time frame: Baseline and Week 52

  18. Change from Baseline in Hemoglobin A1c (HbA1c) at Week 52

    Time frame: Baseline and Week 52

  19. Change from Baseline in Fasting Glucose at Week 52

    Time frame: Baseline and Week 52

  20. Percent Change from Baseline in Fasting Insulin at Week 52

    Time frame: Baseline and Week 52

  21. Plasma Concentration of Maridebart Cafraglutide at Week 52

    Time frame: Week 52

  22. Number of Participants Experiencing Treatment-emergent adverse events (TEAEs)

    Time frame: From first dose to end of trial (up to approximately 65 weeks)

  23. Number of Participants Experiencing Serious AEs (SAEs)

    Time frame: From screening to end of trial (up to approximately 69 weeks)

08

Study locations

23 sites
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 17 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2027 → Aug 2027 and completion Dec 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 27, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Aug 25, 2027was Sep 2027
CompletionEst.
Nov 17, 2027was Dec 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 28, 2026
Primary completion
Sep 29, 2027→Aug 25, 2027
Sep 28, 2026
Study completion
Dec 22, 2027→Nov 17, 2027
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 29, 2027→Aug 25, 2027
    Study completion Dec 22, 2027→Nov 17, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07441252
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 5, 2026
Primary completion
Aug 25, 2027 (estimated)
Completion
Nov 17, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion